Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer|HER-2 Gene Amplification|HER2 Positive Breast Carcinoma|HER-2 Protein Overexpression|Breast Cancer, Male|Breast Cancer Female
Interventions: BIOLOGICAL: HER2 DC1 Vaccine
Sponsor: H. Lee Moffitt Cancer Center and Research Institute